In this study, we hypothesized that SGLT2 inhibitors elicit more cardioprotective effects than DPP-4 inhibitors, specifically in patients with early-stage T2DM and without CVD (including not having heart failure). This evidence concerns the gene SLC5A2 and heart failure.